Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

ReachMD CME

Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

3M ago

MP3•Episode home

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on June 06, 2025 01:14 (6d ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

CME credits: 0.50
Valid until: 26-03-2026
Claim your CME credit at https://reachmd.com/programs/cme/antibody-drug-conjugates-in-bladder-cancer-guideline-updates-and-adverse-event-management/29174/
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.

436 episodes

#Science #Health and Well-Being #Medicine #ReachMD